However, the origin, differentiation, and mechanism of activation of CD4+CD25+ T cells in breast cancer patients and the homogeneity and heterogeneity of negative regulation of CD4+ CD25+ T cells remain to be elucidated for breast cancer. This evidence concerns the gene CD4 and breast cancer.